Clinical Trial Update: A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial update comparing Izalontamab Brengitecan with standard chemotherapy in previously untreated, locally advanced, recurrent inoperable, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Chemotherapy (chemotherapy)
• Izalontamab Brengitecan

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Breast Neoplasms | Phase 2, Phase 3 | Status: RECRUITING